KalVista Pharmaceuticals Reports Incentive Grants Pursuant to Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Massachusetts & SALISBURY, England, October 2, 2024–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the Compensation Committee of KalVista’s Board of Directors has granted incentive options to six newly hired employees to purchase a total of 31,000 shares of KalVista common stock on October 1, 2024 as incentive material for every employee who starts a job at KalVista. The options were granted pursuant to Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $11.39 per share, which was the closing price of KalVista common stock on the grant date. One-quarter of the options vest on the one-year anniversary of the start of the vesting period and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee’s continued service with the company. Each stock option has a term of 10 years and is subject to the terms of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.

About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company committed to developing and commercializing oral medicines for diseases with significant unmet needs. The company focuses on understanding patients’ needs and the limitations of current therapies to develop treatments that enable people to better manage their disease and improve their lives. In August 2024, the Company announced that its NDA for sebetralstat for the treatment of hereditary angioedema (HAE) was accepted by the U.S. FDA with a PDUFA target date of June 17, 2025. In addition, KalVista has received validation of its MAA for HAE from the EMA and has submitted MAA applications to regulatory authorities in the United Kingdom, Switzerland, Australia and Singapore.

For more information about KalVista, visit www.kalvista.com or follow us on social media at @KalVista and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241002290608/en/

Contacts

KalVista Pharmaceuticals, Inc.

Media:
Jenn Snyder
Vice President, Corporate Affairs
(857) 356-0479
[email protected]

Investors:
Ryan Baker
Head of Investor Relations
(617) 771-5001
[email protected]